Biomarker & Intervention Discovery

ADHD

This page lists 9 druggable gene targets, 37 approved or trial-tested drug candidates and 15 recent clinical trials for ADHD, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

NIH funding$73MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous remission by adulthood: 30-70% symptom reduction (depending on definition); functionally impairing ADHD…
Best-intervention remissionStimulant medications (methylphenidate, amphetamines): 60-80% response rate; MTA study: combined medication +…
Gap sizeModerate — substantial underdiagnosis especially in girls/women and adults; treatment gaps exist but pharmacotherapy…
Primary barrieraccess/framing
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous remission by adulthood: 30-70% symptom reduction (depending on definition); functionally impairing ADHD persists into adulthood in 50-65% of childhood cases; DSMIV criteria met in adulthood in ~50%
Best-intervention remission
Stimulant medications (methylphenidate, amphetamines): 60-80% response rate; MTA study: combined medication + behavioural treatment superior to either alone; behavioural interventions alone: 30-50% symptom reduction in children; non-stimulant (atomoxetine, viloxazine): 40-60% response
Gap size
Moderate — substantial underdiagnosis especially in girls/women and adults; treatment gaps exist but pharmacotherapy is highly effective when accessed
Primary barrier
access/framing
Stimulant shortages (2022-present in US) have left many patients without medication; adult ADHD massively underdiagnosed for decades; medication diversion concerns create barriers to legitimate access; non-pharmacological approaches (CBT, exercise, dietary interventions) chronically under-supported

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ADRA2A 281COMT 176DRD2 372DRD4 247HTR1B 266MAOA 233SLC6A2 281SLC6A3 187SNAP25 11
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FADOLMIDINE HYDROCHLORIDE ↑ activates Mechanistic
FIPAMEZOLE ↓ inhibits Mechanistic
ERGOLOID MESYLATES ↓ inhibits Mechanistic
BRIMONIDINE ↑ activates Mechanistic
CLONIDINE HYDROCHLORIDE ↑ activates Mechanistic
ERGOLOID MESYLATES, USP ? unclear Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
NICERGOLINE ? unclear Mechanistic
YOHIMBINE ↓ inhibits Mechanistic 0.42 nM (Ki)
DEXMEDETOMIDINE HYDROCHLORIDE ↑ activates Mechanistic
GUANIDINE HYDROCHLORIDE ? unclear Mechanistic
MEPERIDINE HYDROCHLORIDE ? unclear Mechanistic
BRIMONIDINE TARTRATE ↑ activates Mechanistic
NOREPINEPHRINE ↑ activates Mechanistic 66.0 nM (Ki)
MK-912 ↓ inhibits Mechanistic
LOFEXIDINE ↑ activates Mechanistic
PIRIBEDIL ↓ inhibits Mechanistic
BENZPHETAMINE ? unclear Mechanistic
[125I]P-IODOCLONIDINE ↑ activates Mechanistic
GUANFACINE HYDROCHLORIDE ↑ activates Mechanistic
DOXAZOSIN MESYLATE ? unclear Mechanistic
EPINEPHRINE ↑ activates Mechanistic
DROXIDOPA ↑ activates Mechanistic
PSEUDOEPHEDRINE POLISTIREX ? unclear Mechanistic
RX821002 ↓ inhibits Mechanistic
MUSCARINIC TOXIN 3 ↓ inhibits Mechanistic
TOLAZOLINE ↓ inhibits Mechanistic
PHENTOLAMINE ↓ inhibits Mechanistic 2.6 nM (Ki)
METHYLDOPATE HYDROCHLORIDE ? unclear Mechanistic
TETRAHYDROZOLINE HYDROCHLORIDE ↑ activates Mechanistic
DIPIVEFRIN HYDROCHLORIDE ↑ activates Mechanistic
NAPHAZOLINE HYDROCHLORIDE ↑ activates Mechanistic
RAUWOLFIA SERPENTINA ↓ inhibits Mechanistic 8.2 nM (Ki)
GUANABENZ ↑ activates Mechanistic
ASENAPINE ? unclear Mechanistic
SPIROXATRINE ↓ inhibits Mechanistic
GUANABENZ ACETATE ↑ activates Mechanistic
BRL44408 ↓ inhibits Mechanistic
BETHANIDINE ? unclear Mechanistic
LOFEXIDINE HYDROCHLORIDE ↑ activates Mechanistic

Showing top 40 of 281 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ENTACAPONE ↓ inhibits Mechanistic 386.0 nM (IC50)
TOLCAPONE ↓ inhibits Mechanistic 127.0 nM (IC50)
HYDROCODONE POLISTIREX ? unclear Mechanistic
SUMATRIPTAN ? unclear Mechanistic
QUETIAPINE FUMARATE ? unclear Mechanistic
RASAGILINE ? unclear Mechanistic
PREGABALIN ? unclear Mechanistic
NALTREXONE ? unclear Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
PROPRANOLOL HYDROCHLORIDE ? unclear Mechanistic
ACETAMINOPHEN ? unclear Mechanistic
CODEINE ANHYDROUS ? unclear Mechanistic
MERCAPTOPURINE ? unclear Mechanistic
OPICAPONE ↓ inhibits Mechanistic 1.0 nM (Ki)
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NEBICAPONE ↓ inhibits Mechanistic
ANALGESIC AGENT ? unclear Mechanistic
ANHYDROUS DEXTROSE ? unclear Mechanistic
GALCANEZUMAB ? unclear Mechanistic
REMIFENTANIL HYDROCHLORIDE ? unclear Mechanistic
FLUVOXAMINE ? unclear Mechanistic
ERGOT ALKALOIDS ? unclear Mechanistic
IBUPROFEN, SODIUM SALT ? unclear Mechanistic
ERENUMAB ? unclear Mechanistic
METHADONE HYDROCHLORIDE ? unclear Mechanistic
FREMANEZUMAB ? unclear Mechanistic
ALFENTANIL ? unclear Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
NALOXONE HYDROCHLORIDE ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL1091983 ↓ inhibits Mechanistic 1.6 nM (Ki)
CHEMBL1091982 ↓ inhibits Mechanistic 6.0 nM (Ki)
CHEMBL1091981 ↓ inhibits Mechanistic 16.6 nM (Ki)
CHEMBL1089539 ↓ inhibits Mechanistic 10.6 nM (Ki)
CHEMBL1089538 ↓ inhibits Mechanistic 17.0 nM (Ki)
CHEMBL1089537 ↓ inhibits Mechanistic 17.0 nM (Ki)
CHEMBL1089536 ↓ inhibits Mechanistic 10.2 nM (Ki)
CHEMBL1091204 ↓ inhibits Mechanistic 1.1 nM (Ki)
CHEMBL1089630 ↓ inhibits Mechanistic 1.3 nM (Ki)

Showing top 40 of 176 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LOXAPINE HYDROCHLORIDE ↓ inhibits Mechanistic
MINAPRINE ↑ activates Mechanistic
SULPIRIDE ↓ inhibits Mechanistic
HALOPERIDOL DECANOATE ↓ inhibits Mechanistic
ZIPRASIDONE MESYLATE ↓ inhibits Mechanistic
METHYLDOPA ANHYDROUS ? unclear Mechanistic
BENPERIDOL ↓ inhibits Mechanistic
FLUSPIRILENE ↓ inhibits Mechanistic
VERALIPRIDE ↓ inhibits Mechanistic
CAFFEINE ? unclear Mechanistic
SUMANIROLE ↑ activates Mechanistic 9.0 nM (Ki)
ZIPRASIDONE ↓ inhibits Mechanistic
METOCLOPRAMIDE HYDROCHLORIDE ? unclear Mechanistic
LUMATEPERONE ↓ inhibits Mechanistic
FLUPENTHIXOL ↓ inhibits Mechanistic
PROCHLORPERAZINE ↓ inhibits Mechanistic
PERAZINE ? unclear Mechanistic
FLUPHENAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
ROPINIROLE ↑ activates Mechanistic
RACLOPRIDE ↓ inhibits Mechanistic
PROMAZINE ↓ inhibits Mechanistic
[3H]PD128907 ↑ activates Mechanistic
MORPHINE SULFATE ? unclear Mechanistic
ALIZAPRIDE ↓ inhibits Mechanistic
PHENYLTOLOXAMINE ? unclear Mechanistic
LOXAPINE ↓ inhibits Mechanistic
CABERGOLINE ↑ activates Mechanistic
BREXPIPRAZOLE ↑ activates Mechanistic
PALIPERIDONE ↓ inhibits Mechanistic
APLINDORE FUMARATE ↑ activates Mechanistic
APOMORPHINE ↑ activates Mechanistic
CARIPRAZINE ↑ activates Mechanistic
MOLINDONE ? unclear Mechanistic
TIAPRIDE ↓ inhibits Mechanistic
ZOTEPINE ↓ inhibits Mechanistic
DOPAMINE ↑ activates Mechanistic
XP21279 ? unclear Mechanistic
PROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
VILAZODONE HYDROCHLORIDE ↑ activates Mechanistic
TRIFLUPROMAZINE ↓ inhibits Mechanistic

Showing top 40 of 372 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHLORPROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
L741742 ↓ inhibits Mechanistic
ERGOLOID MESYLATES ↑ activates Mechanistic
BENPERIDOL ↓ inhibits Mechanistic
ROTIGOTINE ↑ activates Mechanistic
ABT-670 ↑ activates Mechanistic
CHLORPROMAZINE ↓ inhibits Mechanistic
METHOTRIMEPRAZINE ↓ inhibits Mechanistic
PRAMIPEXOLE ? unclear Mechanistic
DOPAMINE ↑ activates Mechanistic
PROMAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
PROPIOMAZINE ? unclear Mechanistic
TERGURIDE ↓ inhibits Mechanistic
PRAMIPEXOLE DIHYDROCHLORIDE ↑ activates Mechanistic
LOXAPINE ↓ inhibits Mechanistic
NEMONAPRIDE ↓ inhibits Mechanistic
CLOTHIAPINE ↓ inhibits Mechanistic
PF-592379 ↑ activates Mechanistic
THIETHYLPERAZINE ? unclear Mechanistic
A-381393 ↓ inhibits Mechanistic
ETICLOPRIDE ↓ inhibits Mechanistic
APOMORPHINE ↑ activates Mechanistic
APOMORPHINE HYDROCHLORIDE ↑ activates Mechanistic
ZIPRASIDONE ? unclear Mechanistic
AMOXAPINE ↓ inhibits Mechanistic
BROMOCRIPTINE MESYLATE ↑ activates Mechanistic
L745870 ↓ inhibits Mechanistic
SULPIRIDE ↓ inhibits Mechanistic
HALOPERIDOL DECANOATE ↓ inhibits Mechanistic
ROPINIROLE HYDROCHLORIDE ↑ activates Mechanistic
PERGOLIDE ↑ activates Mechanistic
U101958 ↓ inhibits Mechanistic
HALOPERIDOL LACTATE ↓ inhibits Mechanistic
PROCHLORPERAZINE ↓ inhibits Mechanistic
OLANZAPINE ↓ inhibits Mechanistic
ETILEVODOPA ? unclear Mechanistic
SERTINDOLE ↓ inhibits Mechanistic
[3H]NGD941 ↓ inhibits Mechanistic
PIMOZIDE ↓ inhibits Mechanistic
TRIFLUOPERAZINE ↓ inhibits Mechanistic

Showing top 40 of 247 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
ROXINDOLE ↑ activates Mechanistic
SUMATRIPTAN ↑ activates Mechanistic 7.7 nM (Ki)
OXYMETAZOLINE HYDROCHLORIDE ↑ activates Mechanistic
[3H]ELETRIPTAN ↑ activates Mechanistic
RITANSERIN ↓ inhibits Mechanistic
NEFAZODONE ? unclear Mechanistic
METHYSERGIDE ↓ inhibits Mechanistic
ELETRIPTAN ↑ activates Mechanistic
DIPROPYL-5-CT ↑ activates Mechanistic
NARATRIPTAN ↑ activates Mechanistic
LISURIDE ↑ activates Mechanistic
ZOLMITRIPTAN ↑ activates Mechanistic 6.166 nM (IC50)
DIHYDROERGOTAMINE MESYLATE ↑ activates Mechanistic
TERGURIDE ↑ activates Mechanistic
[3H]SUMATRIPTAN ↑ activates Mechanistic
SB 224289 ↓ inhibits Mechanistic
(R)-FLUROCARAZOLOL ↓ inhibits Mechanistic
5-(NONYLOXY)-TRYPTAMINE ↑ activates Mechanistic
BMS 181,101 ↑ activates Mechanistic
RIZATRIPTAN BENZOATE ↑ activates Mechanistic
ALNIDITAN ↑ activates Mechanistic
ELZASONAN HYDROCHLORIDE ↓ inhibits Mechanistic
CABERGOLINE ↑ activates Mechanistic
[3H]GR 125,743 ↓ inhibits Mechanistic
SB 649915 ↓ inhibits Mechanistic
SERTINDOLE ↓ inhibits Mechanistic
AVITRIPTAN ↑ activates Mechanistic
RISPERIDONE ↓ inhibits Mechanistic
DEXFENFLURAMINE HYDROCHLORIDE ↑ activates Mechanistic
OCAPERIDONE ↓ inhibits Mechanistic
ELETRIPTAN HYDROBROMIDE ↑ activates Mechanistic
DONITRIPTAN ↑ activates Mechanistic
SB236057 ↓ inhibits Mechanistic
TFMPP ↑ activates Mechanistic
SB 714786 ↓ inhibits Mechanistic
CLOZAPINE ↑ activates Mechanistic
ALMOTRIPTAN ↑ activates Mechanistic
CP94253 ↑ activates Mechanistic
RU 24969 ↑ activates Mechanistic
1-NAPHTHYLPIPERAZINE ↑ activates Mechanistic

Showing top 40 of 266 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CX157 ? unclear Mechanistic
MOCLOBEMIDE ↓ inhibits Mechanistic
LADOSTIGIL ? unclear Mechanistic 85000.0 nM (IC50)
BIFEMELANE ↓ inhibits Mechanistic
METHAMPHETAMINE ? unclear Mechanistic
MINAPRINE HYDROCHLORIDE ↓ inhibits Mechanistic
CHEMBL:CHEMBL2088303 ? unclear Mechanistic
PARGYLINE HYDROCHLORIDE ↓ inhibits Mechanistic
ISOCARBOXAZID ↓ inhibits Mechanistic
TRANYLCYPROMINE SULFATE ↓ inhibits Mechanistic
CR4056 ↓ inhibits Mechanistic
TRANYLCYPROMINE ↓ inhibits Mechanistic
CHEMBL:CHEMBL1927670 ? unclear Mechanistic
INDANTADOL ↓ inhibits Mechanistic
CHEMBL:CHEMBL2088301 ? unclear Mechanistic
PSORALEN ? unclear Mechanistic
CLORGILINE ↓ inhibits Mechanistic
VITAMIN K3 ? unclear Mechanistic
IPRONIAZID ↓ inhibits Mechanistic
MINAPRINE ↓ inhibits Mechanistic
PHENELZINE ↓ inhibits Mechanistic
CHEMBL:CHEMBL1642672 ? unclear Mechanistic
1-PHENETHYLPIPERIDINE ? unclear Mechanistic
CHEMBL:CHEMBL602466 ? unclear Mechanistic
MEBANAZINE ↓ inhibits Mechanistic
SELEGILINE ↓ inhibits Mechanistic 1200.0 nM (IC50)
ACACETIN ↓ inhibits Mechanistic
HARMINE ? unclear Mechanistic
LINEZOLID ↓ inhibits Mechanistic 20000.0 nM (Ki)
HARMALINE ↓ inhibits Mechanistic
NICOTINE POLACRILEX ? unclear Mechanistic
CHEMBL:CHEMBL1927684 ? unclear Mechanistic
PHENELZINE SULFATE ↓ inhibits Mechanistic
PIPERINE ? unclear Mechanistic
ANTIDEPRESSANT AGENT ? unclear Mechanistic
PROXIBARBAL ↑ activates Mechanistic
CHEMBL:CHEMBL1813518 ? unclear Mechanistic
NIALAMIDE ↓ inhibits Mechanistic
BEFLOXATONE ↓ inhibits Mechanistic
TRYPTAMINE ? unclear Mechanistic

Showing top 40 of 233 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
GUANETHIDINE ? unclear Mechanistic
BUPROPION HYDROCHLORIDE ↓ inhibits Mechanistic
TRIMIPRAMINE ↓ inhibits Mechanistic
DIETHYLPROPION ? unclear Mechanistic
LEVOMILNACIPRAN ↓ inhibits Mechanistic
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic
DULOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic
DASOTRALINE ↓ inhibits Mechanistic
SERDEXMETHYLPHENIDATE ↓ inhibits Mechanistic
ZOTEPINE ↓ inhibits Mechanistic
LOFEPRAMINE ↓ inhibits Mechanistic
LISDEXAMFETAMINE DIMESYLATE ? unclear Mechanistic
NEFAZODONE ↓ inhibits Mechanistic 360.0 nM (Kd)
3-IODOBENZYLGUANIDINE ? unclear Mechanistic
PHENTERMINE RESIN ? unclear Mechanistic
REBOXETINE ↓ inhibits Mechanistic 1.1 nM (Ki)
NORZOTEPINE ↓ inhibits Mechanistic
ATOMOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic
SERDEXMETHYLPHENIDATE CHLORIDE ↓ inhibits Mechanistic
SOLRIAMFETOL ↓ inhibits Mechanistic
DESIPRAMINE ↓ inhibits Mechanistic
METHYLPHENIDATE ↓ inhibits Mechanistic
AMPRELOXETINE ↓ inhibits Mechanistic
MILNACIPRAN ↓ inhibits Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
AMITRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic
[3H]NISOXETINE ↓ inhibits Mechanistic
PHENDIMETRAZINE TARTRATE ↓ inhibits Mechanistic
LEVOMILNACIPRAN HYDROCHLORIDE ↓ inhibits Mechanistic
METHAMPHETAMINE HYDROCHLORIDE ↓ inhibits Mechanistic
AMITIFADINE HYDROCHLORIDE ? unclear Mechanistic
AMOXAPINE ↓ inhibits Mechanistic
QUETIAPINE FUMARATE ↓ inhibits Mechanistic
AMITIFADINE ? unclear Mechanistic
VENLAFAXINE HYDROCHLORIDE ↓ inhibits Mechanistic
HINOKININ ? unclear Mechanistic
TESOFENSINE ? unclear Mechanistic
TEDATIOXETINE ? unclear Mechanistic
MAZINDOL ↓ inhibits Mechanistic 18.0 nM (Ki)
AMPHETAMINE ASPARTATE ? unclear Mechanistic

Showing top 40 of 281 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
DASOTRALINE ↓ inhibits Mechanistic
MAZINDOL ↓ inhibits Mechanistic 42.6 nM (IC50)
BUPROPION HYDROBROMIDE ↓ inhibits Mechanistic
SIBUTRAMINE ↓ inhibits Mechanistic
METHYLPHENIDATE ↓ inhibits Mechanistic
3,4-METHYLENEDIOXYMETHAMPHETAMINE ? unclear Mechanistic
LISDEXAMFETAMINE DIMESYLATE ? unclear Mechanistic
TESOFENSINE ↓ inhibits Mechanistic
PHENDIMETRAZINE TARTRATE ↓ inhibits Mechanistic
LEVOMILNACIPRAN ↓ inhibits Mechanistic
BUPROPION HYDROCHLORIDE ↓ inhibits Mechanistic
AMPHETAMINE ADIPATE ? unclear Mechanistic
ANESTHETIC AGENT ? unclear Mechanistic
TRIMIPRAMINE ↓ inhibits Mechanistic
AMPHETAMINE ASPARTATE ? unclear Mechanistic
RTI-336 ? unclear Mechanistic
HINOKININ ? unclear Mechanistic
[3H]GBR12935 ↓ inhibits Mechanistic
METYROSINE ? unclear Mechanistic
DIETHYLPROPION HYDROCHLORIDE ↓ inhibits Mechanistic
CLOMIPRAMINE ↓ inhibits Mechanistic
SERDEXMETHYLPHENIDATE CHLORIDE ↓ inhibits Mechanistic
METHYLPHENIDATE HYDROCHLORIDE ? unclear Mechanistic
PHENMETRAZINE ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
COMPOUND 58 [PMID: 25037917] ↓ inhibits Mechanistic
SOLRIAMFETOL ↓ inhibits Mechanistic
ALTROPANE ? unclear Mechanistic
TOLUDESVENLAFAXINE ↓ inhibits Mechanistic
DEXTROAMPHETAMINE SACCHARATE ? unclear Mechanistic
PYROVALERONE HYDROCHLORIDE ↓ inhibits Mechanistic
DESVENLAFAXINE SUCCINATE ↓ inhibits Mechanistic
PHENTERMINE RESIN ? unclear Mechanistic
AMITIFADINE HYDROCHLORIDE ? unclear Mechanistic
PHENELZINE ↓ inhibits Mechanistic
BICIFADINE ↓ inhibits Mechanistic
PSEUDOEPHEDRINE POLISTIREX ? unclear Mechanistic
PHENMETRAZINE HYDROCHLORIDE ↓ inhibits Mechanistic
DEXTROAMPHETAMINE ADIPATE ? unclear Mechanistic
NOMIFENSINE ↓ inhibits Mechanistic

Showing top 40 of 187 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
INCOBOTULINUMTOXINA ↓ inhibits Mechanistic
PRABOTULINUMTOXIN A ? unclear Mechanistic
THERAPEUTIC STEROID HORMONE ? unclear Mechanistic
AMISULPRIDE ? unclear Mechanistic
DAXIBOTULINUMTOXINA ↓ inhibits Mechanistic
TRENIBOTULINUMTOXINE ? unclear Mechanistic
LETIBOTULINUMTOXINA ? unclear Mechanistic
ONABOTULINUMTOXINA ↓ inhibits Mechanistic
BOTULINUM TOXIN TYPE A ? unclear Mechanistic
DIAZOXIDE ? unclear Mechanistic
ABOBOTULINUMTOXINA ? unclear Clinical

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is ADHD: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT06931080 Phase: 2/3 Started: 2025-04-30

The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in adult ADHD patients.

NCT06926829 Phase: 3 Started: 2025-06-25

The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan

NCT07717879 Phase: 3 Started: 2026-07-06

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \<12 years with ADHD.

NCT07717892 Phase: 3 Started: 2026-06-25

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.

NCT07755410 Phase: 2 Started: 2026-08-10

The purpose of this study is to measure safety and the improvement in symptoms in subjects with ADHD when taking ALKS 7290 tablets compared with placebo tablets.

NCT06967857 Phase: 2 Started: 2025-05-15

The indication of attention-deficit/hyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least one psychiatric comorbidity in their lives. Depression is one of the most common comorbidities in patients with ADHD. The...

NCT05842330 Phase: 3 Started: 2024-01-01

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD ...

NCT04240756 Phase: 3 Started: 2020-08-06

This study will compare the effectiveness of combined parental stimulant medication and behavioral parent training (BPT) versus BPT alone on child ADHD-related impairment (primary outcome), child ADHD and externalizing symptoms, time to child stimulant prescription (secondary child outcomes) and par...

NCT07300956 Phase: 4 Started: 2026-02-16

This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.

NCT07777328 Phase: N/A Started: 2025-11-25

The aim of this project is to look at the impact of 5-Hydroxytryptophan (5-HTP) on distractibility. 5-HTP is the precursor to the neurotransmitter serotonin and is a chemical that the body produces naturally. There is evidence that distractibility is associated with a decreased level of serotonin. T...

NCT07594652 Phase: 4 Started: 2026-05-29

This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.

NCT07459699 Phase: N/A Started: 2026-05-25

The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.

NCT05631626 Phase: 3 Started: 2022-12-29

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.

NCT06359899 Phase: 3 Started: 2024-05-28

This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with Attention Deficit Hyperactivity Disorder(ADHD).

NCT07592390 Phase: 1/2 Started: 2026-05-01

This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsi...


Agents Found By Disease-Level Search

Searched directly from “ADHD” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

37 agents shown (approved or with trial evidence) — 33 not found by the gene-target search above.

Atomoxetine

Approved · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT00418262 NCT00716274 NCT03936491

Methylphenidate

Approved · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT03936491 NCT07314333 NCT04349917

OROS methylphenidate HClNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00269802 NCT00269776

RitalinNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00269802 NCT01831622

Lisdexamfetamine

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01924429 NCT07314333

ConcertaNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT02730572 NCT05650775

Centanafadine SRNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT03605836 NCT03605836

Coping PowerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02488499

Individualized TreatmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02488499

BCINOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01344044

viloxazine (SPN-812)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT06185985

FRx-001NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05710965

FRx-003NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05710965

FRx-004NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05710965

GABANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04144439

fasoracetam (AEVI-001)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03609619

Clinical evaluationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04769011

Neuropsychological evaluationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04769011

Neurophysiological evaluationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04769011

Genetic evaluationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04769011

Stimulant Diversion Prevention (SDP)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03080259

QbTestNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03368573

EB-1020 (Centanafadine) 164.4 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06926829

EB-1020 (Centanafadine) 328.8 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06926829

HLD200 methylphenidate hydrochloride (MPH) CapsulesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02493777

Spanish-Language Unstuck and On Target (SL-Unstuck)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07571434

Drive funNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05832957

Concerta AG formulationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02730572

Concerta EG formulationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02730572

Usual treatment for ADHDNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06006871

dasotraline

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03231800

Mindful Awareness Practices (MAPs)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05584475

Stimulant medication therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00632619

Community-based psychosocial treatmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00632619

Motor Proficiency in School Age ADHD: Contribution of Different ComorbiditiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04494230

Serdexmethylphenidate/dexmethylphenidateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06000501

CLS-FUERTENOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02888821

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.